Insmed To Participate in Five September Conferences

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on serious and rare diseases, will participate in several upcoming virtual investor events. These include the Citi BioPharma Virtual Conference on September 8, Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 13, among others. Each session will be webcast and available for 30 days following. Insmed aims to transform patient lives with its therapies, including a first-in-disease treatment for a chronic lung disease.

BRIDGEWATER, N.J., Sept. 1, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events:

• Citi's 16^th Annual BioPharma Virtual Conference on September 8, 2021 at 9:45 a.m. ET in a fireside chat
• The Morgan Stanley 19^th Annual Global Healthcare Conference on September 9, 2021 at 3:30 p.m. ET in a fireside chat
• The H.C. Wainwright 23^rd Annual Global Investment Conference on September 13, 2021 at 7:00 a.m. ET in a fireside chat available for on-demand viewing
• SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event on September 22, 2021 in 1x1 investor meetings
• The Cantor Fitzgerald Virtual Global Healthcare Conference on September 27, 2021 at 8:00 a.m. ET in a fireside chat

Each fireside chat will be webcast and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the respective presentation dates.

About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-participate-in-five-september-conferences-301366701.html

SOURCE Insmed Incorporated

FAQ

What upcoming investor events will Insmed (INSM) participate in September 2021?

Insmed will participate in the Citi BioPharma Conference on September 8, Morgan Stanley Healthcare Conference on September 9, H.C. Wainwright Global Investment Conference on September 13, SVB Leerink CybeRx Series on September 22, and Cantor Fitzgerald Healthcare Conference on September 27.

What is the date and time of Insmed's fireside chat at the Citi BioPharma Conference?

Insmed's fireside chat at the Citi BioPharma Conference is scheduled for September 8, 2021, at 9:45 a.m. ET.

Where can I access the webcasts of Insmed's investor events?

The webcasts of Insmed's investor events can be accessed in the investor relations section of their website at www.insmed.com.

How long will the webcasts of Insmed's presentations be available?

The webcasts will be archived for 30 days following each respective presentation date.

What type of therapies does Insmed focus on?

Insmed focuses on therapies for serious and rare diseases, including a first-in-disease treatment for a chronic lung disease.